A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia

INTRODUCTION: The safety and efficacy of the novel α7 nicotinic acetylcholine receptor agonist ABT-126 were investigated in subjects with mild-to-moderate Alzheimer's dementia (AD). METHODS: Subjects not currently receiving acetylcholinesterase inhibitors were randomized to ABT-126 (5 or 25 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Gault, Laura M., Ritchie, Craig W., Robieson, Weining Z., Pritchett, Yili, Othman, Ahmed A., Lenz, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974973/
https://www.ncbi.nlm.nih.gov/pubmed/29854928
http://dx.doi.org/10.1016/j.trci.2015.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974973/
https://www.ncbi.nlm.nih.gov/pubmed/29854928
http://dx.doi.org/10.1016/j.trci.2015.06.001

Ejemplares similares